2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.69

PP01.69 - Fei Li

Pdf Summary

The study by Ning Han and Fei Li aims to assess the prognostic value of certain hematological parameters, specifically lymphocyte and direct bilirubin counts, in patients with liver metastasis from lung cancer before any treatment. Data were gathered from 142 patients at the Liaoning Cancer Hospital & Institute between January 2019 and December 2020. The study group comprised 110 males and 32 females, aged between 46 and 79, with different lung cancer types: 66 with small-cell lung cancer, 36 with adenocarcinoma, 30 with squamous carcinoma, and 10 with other special types.<br /><br />Univariate and multivariate analyses identified pre-treatment lymphocyte and direct bilirubin counts as critical indicators. Univariate analysis linked several factors with poor prognosis, but multivariate analysis specifically highlighted low pre-treatment lymphocyte count and high pre-treatment direct bilirubin count as independent risk factors for poorer outcomes. ROC curve analyses further supported these findings, although the AUC values (0.21 for lymphocytes and 0.43 for direct bilirubin) suggest the predictive power may be quite limited.<br /><br />In conclusion, the study finds that low lymphocyte levels and elevated direct bilirubin levels before treatment are associated with a poorer prognosis for lung cancer patients with liver metastasis. Such insights could aid in developing tailored treatment approaches and improve prognostic assessments in these patients.

Keywords

prognostic value

hematological parameters

lymphocyte count

direct bilirubin

liver metastasis

lung cancer

univariate analysis

multivariate analysis

ROC curve

prognostic assessment